Letter to the Editor

Letter to the Editor

Reply to Perugula et al: Toward Improving Reliability of Safety Information on Drug Exposure in Pregnancy

November 30, 2022

Naho Yakuwa, BPharm, responds to Perugula and colleagues about a recent study on SGA use during early pregnancy.

Letter to the Editor

Stigma Kills Psychiatric Patients and Is Now Killing Clinical Research Too

November 28, 2022

Robert M. Post, MD, argues that NIMH should abandon the RDoC framework and restore funding for clinical research.

Letter to the Editor

Valproate Prescribing in Individuals of Childbearing Age

October 12, 2022

Camille Tastenhoye, MD, and colleagues share data from a tertiary care women’s hospital that highlight opportunities for improvement in valproate prescribing practices.

Letter to the Editor

Addressing the Problem of Prescription of Valproate to Women of Childbearing Age: Reply to Tastenhoye et al

October 12, 2022

Chittaranjan Andrade, MD, responds to a letter by Tastenhoye et al and comments on his recent study on valproate prescription in women.

Letter to the Editor

Asenapine, Aggression, and Affinity

September 28, 2022

Dr El-Mallakh comments on a recent study by Citrome et al and discusses his group’s research on antiaggression effects of clozapine.

Letter to the Editor

A Mirror-Image Trial or Smoke and Mirrors? Phase 3b Study on Digital Aripiprazole

August 3, 2022

This letter comments on methodological aspects of a recent study by Cohen et al.